论文部分内容阅读
目的:评价纤维蛋白胶复合平阳霉素栓塞硬化治疗面颈部静脉畸形的临床效果。方法:回顾2005年1月—2012年1月应用纤维蛋白胶复合平阳霉素栓塞硬化技术治疗的78例面颈部静脉畸形患者资料。63例患者接受纤维蛋白胶/平阳霉素栓塞硬化+平阳霉素注射治疗,15例患者除上述治疗外,还接受了无水乙醇硬化、射频消融或手术治疗。治疗后观察患者生命体征及症状,拍摄胸片了解肺部情况。通过临床观察、B超、MRI检查评价治疗效果。随访时间6个月～7 a。结果:78例患者中,男41例,女37例;年龄10岁～66岁(平均26岁)。67例(85.9%)病变消退率大于90%,11例(14.1%)大于50%。6例患者出现高热,未发现过敏反应、肺栓塞或其他并发症。结论:纤维蛋白胶/平阳霉素栓塞硬化技术安全、有效,并发症在可接受范围,适用于治疗大范围、高回流静脉畸形。
Objective: To evaluate the clinical effect of fibrin glue combined with pingyangmycin in the treatment of facial and cervical venous malformations. Methods: The data of 78 patients with facial and cervical venous malformation treated with fibrin glue and pingyangmycin embolization sclerotherapy from January 2005 to January 2012 were retrospectively reviewed. 63 patients received fibrin glue / pingyangmycin embolization + pingyangmycin injection treatment, 15 patients in addition to the above treatment, but also received absolute ethanol sclerosis, radiofrequency ablation or surgery. After treatment, the patient’s vital signs and symptoms were observed, chest radiography was taken to understand the condition of the lungs. Through clinical observation, B ultrasound, MRI examination to evaluate the therapeutic effect. The follow-up time ranged from 6 months to 7 years. Results: Of the 78 patients, 41 were males and 37 were females; their ages ranged from 10 years to 66 years (mean, 26 years). 67 patients (85.9%) had a regression rate of more than 90% and 11 (14.1%) were more than 50%. Six patients developed hyperthermia, no allergic reactions, pulmonary embolism or other complications. Conclusion: Fibrin glue / pingyangmycin embolization sclerotherapy is safe, effective and has acceptable complication in the treatment of large-area, high-reflux venous malformations.